30 Day Trial

ORTHOWORLD » Other Articles of Interest

Changes at the helms of SkelRegen, ETEX

SkelRegen, a leader in small molecule musculoskeletal tissue regeneration and the first to identify multiple small molecules that are osteoinductive and target different aspects of the skeletal tissue formation pathway, has appointed Todd F. La Neve, J.D. as CEO.

Stephen R. La Neve, former SkelRegen CEO, will continue to serve as co-founder and director and recently accepted the position of President and Chief Executive Officer at ETEX.

Read the full releases from SkelRegen and ETEX online.